Summary & Overview
HCPCS G2092: ACE/ARB/ARNI Therapy Prescribed or Currently Taken
HCPCS Level II code G2092 indicates that a patient is prescribed or currently taking an ACE inhibitor, ARB, or ARNI. Nationally, documentation of renin‑angiotensin system therapy is important for quality measurement, continuity of care, and tracking guideline‑directed medical therapy for cardiovascular and renal conditions. Clear capture of this medication status supports treatment decisions, performance measurement, and population health management.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for G2092, the typical service settings where the code is used, and what to expect in payer coverage and coding practice. The publication addresses where this code fits within outpatient medication reconciliation workflows and how it supports documentation of guideline‑recommended therapies.
The report provides benchmarks and policy context where available, summarizes common billing practices associated with medication‑status codes, and outlines clinical scenarios in which G2092 is commonly reported. Data not available in the input are noted explicitly in specific sections of the full publication.
Billing Code Overview
HCPCS Level II code G2092 documents that angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) or angiotensin receptor‑neprilysin inhibitor (ARNI) therapy is prescribed or currently being taken. This entry captures prescription status for medications that act on the renin‑angiotensin system and related pathways.
-
Service type: Medication therapy documentation and ambulatory medication management
-
Typical site of service: Outpatient clinics, primary care offices, cardiology practices, and other ambulatory care settings where medication reconciliation and prescription management occur
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with a history of hypertension and heart failure with reduced ejection fraction presents to a primary care clinic for a medication management visit. The clinician reviews current medications, blood pressure, renal function (serum creatinine and eGFR), and serum potassium. The patient reports adherence but notes intermittent dizziness on standing. The clinician verifies that the patient is taking an angiotensin converting enzyme inhibitor (ACE inhibitor) therapy and documents the medication name and dose in the chart. If therapy is not yet initiated, the clinician prescribes an ACE inhibitor, angiotensin receptor blocker (ARB), or angiotensin receptor‑neprilysin inhibitor (ARNI) and documents indication, baseline labs ordered (BMP for potassium and creatinine), counseling on potential side effects (hyperkalemia, renal impairment, cough for ACE inhibitors), and follow-up monitoring. Typical workflow includes medication reconciliation by nursing, vitals and lab review, clinician evaluation, prescription entry or continuation, and coding/billing for therapy prescribed or currently taken under G2092.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the visit required substantially greater resources (e.g., complex medication reconciliation and extensive counseling) than typical for documenting ACE/ARB/ARNI therapy. |